Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
- PMID:29461039
- DOI: 10.1021/acschemneuro.8b00043
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
Abstract
Lysergic acid diethylamide (LSD) is one of the most potent psychoactive agents known, producing dramatic alterations of consciousness after submilligram (≥20 μg) oral doses. Following the accidental discovery of its potent psychoactive effects in 1943, it was supplied by Sandoz Laboratories as an experimental drug that might be useful as an adjunct for psychotherapy, or to give psychiatrists insight into the mental processes in their patients. The finding of serotonin in the mammalian brain in 1953, and its structural resemblance to LSD, quickly led to ideas that serotonin in the brain might be involved in mental disorders, initiating rapid research interest in the neurochemistry of serotonin. LSD proved to be physiologically very safe and nonaddictive, with a very low incidence of adverse events when used in controlled experiments. Widely hailed by psychiatry as a breakthrough in the 1950s and early 1960s, clinical research with LSD ended by about 1970, when it was formally placed into Schedule 1 of the Controlled Substances Act of 1970 following its growing popularity as a recreational drug. Within the past 5 years, clinical research with LSD has begun in Europe, but there has been none in the United States. LSD is proving to be a powerful tool to help understand brain dynamics when combined with modern brain imaging methods. It remains to be seen whether therapeutic value for LSD can be confirmed in controlled clinical trials, but promising results have been obtained in small pilot trials of depression, anxiety, and addictions using psilocybin, a related psychedelic molecule.
Keywords: 5-HT2A receptor; Albert Hofmann; LSD; brain dynamics; consciousness; hallucinogen; lysergic acid diethylamide; mystical experiences; psychedelic; psychotherapy.
Similar articles
- Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration.Oram M.Oram M.Hist Psychiatry. 2016 Sep;27(3):290-306. doi: 10.1177/0957154X16648822. Epub 2016 May 18.Hist Psychiatry. 2016.PMID:27194113
- From Hofmann to the Haight Ashbury, and into the future: the past and potential of lysergic acid diethlyamide.Smith DE, Raswyck GE, Davidson LD.Smith DE, et al.J Psychoactive Drugs. 2014 Jan-Mar;46(1):3-10. doi: 10.1080/02791072.2014.873684.J Psychoactive Drugs. 2014.PMID:24830180Review.
- Albert Hofmann, the father of LSD (1906-2008).Fusar-Poli P, Borgwardt S.Fusar-Poli P, et al.Neuropsychobiology. 2008;58(1):53-4. doi: 10.1159/000157779. Epub 2008 Sep 18.Neuropsychobiology. 2008.PMID:18799895No abstract available.
- Modern Clinical Research on LSD.Liechti ME.Liechti ME.Neuropsychopharmacology. 2017 Oct;42(11):2114-2127. doi: 10.1038/npp.2017.86. Epub 2017 Apr 27.Neuropsychopharmacology. 2017.PMID:28447622Free PMC article.Review.
- Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20th Century.Aday JS, Bloesch EK, Davoli CC.Aday JS, et al.J Psychoactive Drugs. 2019 Jul-Aug;51(3):210-217. doi: 10.1080/02791072.2019.1581961. Epub 2019 Mar 6.J Psychoactive Drugs. 2019.PMID:30836890
Cited by
- Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants.Vizeli P, Studerus E, Holze F, Schmid Y, Dolder PC, Ley L, Straumann I, Becker AM, Müller F, Arikci D, Liechti ME.Vizeli P, et al.Transl Psychiatry. 2024 Sep 4;14(1):357. doi: 10.1038/s41398-024-03074-9.Transl Psychiatry. 2024.PMID:39231959Free PMC article.Clinical Trial.
- Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2A Receptor Agonists.Poulie CBM, Pottie E, Simon IA, Harpsøe K, D'Andrea L, Komarov IV, Gloriam DE, Jensen AA, Stove CP, Kristensen JL.Poulie CBM, et al.J Med Chem. 2022 Sep 22;65(18):12031-12043. doi: 10.1021/acs.jmedchem.2c00702. Epub 2022 Sep 13.J Med Chem. 2022.PMID:36099411Free PMC article.
- Biological studies of clavine alkaloids targeting CNS receptors.Tasker NR, Pazur EJ, Wipf P.Tasker NR, et al.Front Psychiatry. 2023 Nov 21;14:1286941. doi: 10.3389/fpsyt.2023.1286941. eCollection 2023.Front Psychiatry. 2023.PMID:38076698Free PMC article.
- Therapeutic effect of psilocybin in addiction: A systematic review.van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, Kramers K, Schellekens A, Somers M, Bossong MG, Batalla A.van der Meer PB, et al.Front Psychiatry. 2023 Feb 9;14:1134454. doi: 10.3389/fpsyt.2023.1134454. eCollection 2023.Front Psychiatry. 2023.PMID:36846225Free PMC article.
- Pharmacovigilance in perspective: drug withdrawals, data mining and policy implications.Alomar M, Palaian S, Al-Tabakha MM.Alomar M, et al.F1000Res. 2019 Dec 16;8:2109. doi: 10.12688/f1000research.21402.1. eCollection 2019.F1000Res. 2019.PMID:32161643Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous